Biotech development

Q&A: Blackstone Life Sciences head on drug R&D in Asia

Blackstone Life Sciences head Nicholas Galakatos talks regulation and the drug R&D process, and explains how investors can avoid mistakes in the pharmaceutical gold rush.

An ageing population in Asia has expanded the scope for pharmaceutical companies. And countries, in turn, are using regulation to speed up the drug development process as they embrace a dynamic life science market.

¬ Haymarket Media Limited. All rights reserved.

Sign In to Your Account To Access Exclusive FinanceAsia Content!

Please sign in to your subscription to unlock full access to our premium FA resources.

Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial - no registration fees required. Click the link to get started.

Note: This free trial is a one-time offer.

Questions?
If you have any enquiries or would like a quote for a team or company licence, please contact us at [email protected]. Our subscription team will be happy to assist you.

Share our publication on social media
Share our publication on social media